This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join BNMS | Print Page | Contact Us | Sign In
Other Guidelines
Other Guidelines

Diagnostic Thyroid Guidelines

BNMS Guideline under development

Thyroid Therapy

Please note that the British Thyroid Association guideline on the management of thyroid nodules/cancer is advised as the primary source of guidelines in Britain.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Published 2016

Link to guideline

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

Published February 2016

Link to article

British Thyroid Association Guidelines for the Management of Thyroid Cancer

Published July 2014

Link to guideline

Link to guideline page here

(Second edition)

The patient information leaflet can be accessed here

We have developed a patient questionnaire to help us evaluate, review and adjust the patient information leaflet in the future. There is an online survey monkey option -

UK Low Iodine Diet Working Group 2016

The International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging worked together to create this guidance document on the use of somatostatin analogue-based PRRNT.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Guidance Document link

This publication is the result of a collaboration the IAEA and Professional Organizations including the EANM, SNMMI, AOFNMB, ALASBINM and WFNMB and a group of internationally renowned experts.

This publication intends to provide practical support for the introduction of new radiotracers, including recommendations on the necessary steps needed to facilitate and expedite the introduction of radiopharmaceuticals in clinical use, while ensuring that a safe and high quality product is administered to the patient at all times.

Please access the freely downloadable PDF at

View document via the HSCIC website

This report may be of interest to members of the public, policy officials and other stakeholders to make local and national comparisons and to monitor the quality and effectiveness of services.

Author: National Casemix Office Health and Social Care Information Centre

This guidance comprises an up-to-date summary of relevant indications for the use of PET-CT, where there is good evidence that patients will benefit from improved disease assessment resulting in altered management and improved outcomes. The document will be updated annually by the RCP/RCR Intercollegiate Standing Committee on Nuclear Medicine.

To view this guidance follow this link to the Royal College of Radiologists' website LINK

Link to Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and use of sealed radioactive sources, on the ARSAC website

The BTS Guidelines for the investigation and management of pulmonary nodules are now available.

Link to guidelines page here

The new guidance document, entitled Lifelong learning and building teams using peer feedback replaces the previous RCR publication Quality assurance in radiology reporting: peer feedback.

It highlights the importance of peer review and feedback in day-to-day radiology practice, emphasising and giving practical examples as to how peer review should be a routine action for radiology departments and one that helps learning, improves outcomes and promotes teamwork.

The document contains peer review definitions and explanations to aid radiologists and the IT industry that supports image access.

The British Nuclear Cardiology Society has released Procedure Guidelines for Radionuclide Myocardial Perfusion Imaging with Single-Photon Emission Computed Tomography (SPECT), which is endorsed by the BNMS.

Please click here to view

The American Thyroid Association has released Guidelines for the Treatment of Hypothyroidism, which is endorsed by the BNMS.

Please click here to view

The Royal College of Radiologists have announced the online publication of the guideline "Molecular Radiotherapy: Guidance for Clinicians"

Click here to view

The British Thyroid Association has published Guidelines for the Managment of Thyroid Cancer. These can be viewed here

In August 2004 a Supplement to Heart was published which covered the current applications of myocardial perfusion imaging and also its cost effectiveness and use in clinical practice in the UK. This is a valuable source of information for both providers and users of the technique.

It represents a summary of the evidence on which the submission by the professional bodies to the National Institute of Clinical Excellence (NICE) was based, as part of its development of the health technology assessment of this technique.

Constantinos Anagnostopoulos and Richard Underwood - reviewed by Kshama Wechalekar 2016

Myocardial perfusion scintigraphy: the evidence

C Y Loong and C Anagnostopoulos

Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging

T M Bateman and E Prvulovich

Assessment of prognosis in chronic coronary artery disease

J E Udelson and E J Flint

Radionuclide imaging in risk assessment after acute coronary syndromes

J J Bax, E E van der Wall, and M Harbinson

Radionuclide techniques for the assessment of myocardial viability and hibernation

S R Underwood and L J Shaw

Myocardial perfusion scintigraphy and cost effectiveness of diagnosis and management of coronary heart disease

S L Rahman and A D Kelion

Nuclear cardiology in the UK: do we apply evidence based medicine?

Click here if you wish to visit the NICE website

The BNMS are aware that both the EANM and the ARSAC provide guidelines on the calculation of the administered activity required for paediatric Nuclear Medicine procedures. The scaling factors given by the guidelines are different. Members of the BNMS have contacted the Society for advice about which guidelines to follow.

The ARSAC are reviewing the weighing factors that are currently published in the Notes for Guidance (1).

The BNMS advises centres to use the existing ARSAC guidelines until this work is complete.

[1] ARSAC Newsletter 2009

With the rapid expansion of clinical PET-CT in the UK there is an urgent need for guidance on the (state-registered) clinical scientist (CS) support required to deliver the service safely, effectively, in compliance with all relevant regulations, and to the necessary standards set by professional bodies, including ‘Standards for delivering a PET service in the UK’ (Report of the Intercollegiate Standing Committee on Nuclear Medicine, in ‘PET-CT in the UK’, RCR 2005).

These guidelines define the recommended minimum level of clinical scientist support required specifically for PET-CT based on a fixed site and performing FDG oncology studies only. A ‘fixed site’ is a unit where the scanner is permanently installed in a building, and does not include permanently sited mobile units. Additional and specialist scientific and engineering support will be needed where units are operating their own cyclotrons and/or undertaking research. This may be provided in partnership with manufacturers and academic units.

This document has been prepared by a group of clinical scientists from across the UK with extensive experience in PET-CT.

View full document pdf

Reviewed by Claire Greaves 2016

From the Defra website The Environmental Permitting system simplifies permit applications, amendments and variations for both industry and regulator and thereby cuts unnecessary red tape. It allows regulators to focus resources on medium and high-risk operations whilst continuing to protect the environment and human health.

Environmental Permitting was first applied to Waste Management Licensing and Pollution Prevention and Control and will now be extended to further permitting and compliance regimes. The Environmental Permitting (England and Wales) Regulations 2010 have been approved by Parliament and the National Assembly for Wales and will come into force on 6 April 2010.

Environmental Permitting Guidance Radioactive Substances Regulation For the Environmental Permitting (England and Wales) Regulations 2010 March 2010

Version 1.1


© 2013 BNMS unless otherwise stated.
The BNMS is a registered as a company in England and Wales with number 08082786.  The BNMS is a charity governed by the rules of the Charity Commission for England and Wales - Registered Number 1150234.  Registered Office: The Royal College of Physicians, 11 St. Andrew's Place, Regent's Park, London NW1 4LE.
The British Nuclear Medicine Society is not able to give specific clinical advice to members of the public. If you are concerned about your scan or therapy please seek the opinion of a nuclear medicine clinician where you were seen or the clinician who referred you to the department or your GP.
Enquiries related to issues such as internships and work experience opportunities, should be directed to the relevant professional body e.g., for radiologists, this will be the Royal College of Radiologists.